Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 397

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective

Open access
Vickery, Brian P., Berglund, Jelena P., Burk, Caitlin M., Fine, Jason P., Kim, Edwin H., Kim, Jung In, Keet, Corinne A., Kulis, Michael, Orgel, Kelly G., Guo, Rishu, Steele, Pamela H., Virkud, Yamini V., Ye, Ping, Wright, Benjamin L., Wood, Robert A., Burks, A. Wesley·2017·Journal of Allergy and Clinical Immunology

Abstract

Background: Oral immunotherapy (OIT) is an effective experimental food allergy treatment that is limited by treatment withdrawal and the frequent reversibility of desensitization if interrupted. Newly diagnosed preschool children may have clinical and immunological characteristics more amenable to treatment. Objective: We sought to test the safety, effectiveness, and feasibility of early OIT (E‐OIT) in the treatment of peanut allergy. Methods: We enrolled 40 children aged 9 to 36 months with suspected or known peanut allergy. Qualifying subjects reacted to peanut during an entry food challenge and were block‐randomized 1:1 to receive E‐OIT at goal maintenance doses of 300 or 3000 mg/d in a double‐blinded fashion. The primary end point, sustained unresponsiveness at 4 weeks after stopping early intervention oral immunotherapy (4‐SU), was assessed by double‐blinded, placebo‐controlled food challenge either upon achieving 4 prespecified criteria, or after 3 maintenance years. Peanut‐specific immune responses were serially analyzed. Outcomes were compared with 154 matched standard‐care controls. Results: Of 40 consented subjects, 3 (7.5%) did not qualify. Overall, 29 of 37 (78%) in the intent‐to‐treat analysis achieved 4‐SU (300‐mg arm, 17 of 20 [85%]; 3000 mg, 12 of 17 [71%], P = .43) over a median of 29 months. Per‐protocol, the overall proportion achieving 4‐SU was 29 of 32 (91%). Peanut‐specific IgE levels significantly declined in E‐OIT‐treated children, who were 19 times more likely to successfully consume dietary peanut than matched standard‐care controls, in whom peanut‐specific IgE levels significantly increased (relative risk, 19.42; 95% CI, 8.7‐43.7; P < .001). Allergic side effects during E‐OIT were common but all were mild to moderate. Conclusions: At both doses tested, E‐OIT had an acceptable safety profile and was highly successful in rapidly suppressing allergic immune responses and achieving safe dietary reintroduction.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jaci.2016.05.027

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Cited by

See all 397

Metadata

Authors
Vickery, B. P., Berglund, J. P., Burk, C. M., Fine, J. P., Kim, E. H., Kim, J. I., Keet, C. A., Kulis, M., Orgel, K. G., Guo, R., Steele, P. H., Virkud, Y. V., Ye, P., Wright, B. L., Wood, R. A., & Burks, A. W.
Venue
Journal of Allergy and Clinical Immunology
Publisher
Elsevier BV
Published
2017-01
Volume
139
Issue
1
Pages
173-181.e8
ISSN
0091-6749 (ISSN-L)
OpenAlex
W2491611941
Cited by
397
References
34
FWCI
31.89
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective. https://app.cochat.ai/papers/10.1016/j.jaci.2016.05.027
The paper
Vickery, B. P., Berglund, J. P., Burk, C. M., Fine, J. P., Kim, E. H., Kim, J. I., Keet, C. A., Kulis, M., Orgel, K. G., Guo, R., Steele, P. H., Virkud, Y. V., Ye, P., Wright, B. L., Wood, R. A., & Burks, A. W. (2017). Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2016.05.027

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.